Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Uni-Bio Science Group Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Uni-Bio Science Group.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi	39.9%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement

Sep 13

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive

Jul 29

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive

May 27

Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?

Apr 24

Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%

Jan 22

Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement

Oct 24

Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)

Apr 30

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Nov 22

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Jan 05

Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth

Mar 01

Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years

Jan 05

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Nov 23

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Uni-Bio Science Group yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

SEHK:690 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (HKD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	508	99	63	123	N/A
3/31/2024	497	85	51	111	N/A
12/31/2023	485	71	39	99	N/A
9/30/2023	490	67	40	84	N/A
6/30/2023	495	63	41	69	N/A
3/31/2023	467	51	31	59	N/A
12/31/2022	440	39	20	49	N/A
9/30/2022	416	16	-3	15	N/A
6/30/2022	392	-7	-27	-18	N/A
3/31/2022	373	-13	-12	-3	N/A
12/31/2021	353	-20	4	12	N/A
9/30/2021	326	-39	3	14	N/A
6/30/2021	298	-58	2	15	N/A
3/31/2021	254	-65	-13	0	N/A
12/31/2020	209	-71	-28	-15	N/A
9/30/2020	194	-63	-22	-11	N/A
6/30/2020	180	-54	-15	-6	N/A
3/31/2020	195	-26	-27	-18	N/A
12/31/2019	209	2	-40	-31	N/A
9/30/2019	191	-14	-48	-42	N/A
6/30/2019	173	-30	-55	-52	N/A
3/31/2019	154	-85	-73	-71	N/A
12/31/2018	135	-139	-92	-89	N/A
9/30/2018	144	-224	-104	-89	N/A
6/30/2018	153	-309	-116	-90	N/A
3/31/2018	155	-294	N/A	-79	N/A
12/31/2017	156	-279	N/A	-69	N/A
9/30/2017	148	-172	N/A	-49	N/A
6/30/2017	140	-64	N/A	-29	N/A
3/31/2017	143	-60	N/A	-26	N/A
12/31/2016	146	-56	N/A	-24	N/A
9/30/2016	141	-56	N/A	-30	N/A
6/30/2016	135	-55	N/A	-36	N/A
3/31/2016	129	-58	N/A	-29	N/A
12/31/2015	123	-60	N/A	-22	N/A
12/31/2014	122	-57	N/A	-80	N/A
9/30/2014	110	-365	N/A	63	N/A
6/30/2014	106	-366	N/A	56	N/A
3/31/2014	103	-366	N/A	50	N/A
12/31/2013	97	-220	N/A	8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if 690's forecast earnings growth is above the savings rate (2.3%).

Kazançlar ve Piyasa: Insufficient data to determine if 690's earnings are forecast to grow faster than the Hong Kong market

Yüksek Büyüme Kazançları: Insufficient data to determine if 690's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if 690's revenue is forecast to grow faster than the Hong Kong market.

Yüksek Büyüme Geliri: Insufficient data to determine if 690's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if 690's Return on Equity is forecast to be high in 3 years time

Uni-Bio Science Group Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021

Recent updates

Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement

Uni-Bio Science Group Limited (SEHK:690) commences an Equity Buyback Plan for 616,358,814 shares, representing 10% of its issued share capital, under the authorization approved on May 16, 2024.

Uni-Bio Science Group Limited to Report First Half, 2024 Results on Aug 28, 2024

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive

New minor risk - Share price stability

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive

Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: HK$0.011 (vs HK$0.006 in FY 2022)

Uni-Bio Science Group Limited to Report Q4, 2023 Results on Mar 27, 2024

Uni-Bio Science Group Limited Announces the Acceptance of its Marketing Application for Diquafosol Sodium Eye Drops by the China National Medical Products Administration

Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%

Uni-Bio Science Group Limited Announces Approval of Marketing Application of Bogutai (Teriparatide Injection) by the China National Medical Products Administration

Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement

First half 2023 earnings released: EPS: HK$0.006 (vs HK$0.002 in 1H 2022)

Uni-Bio Science Group Limited to Report First Half, 2023 Results on Aug 28, 2023

Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director

Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)

Full year 2022 earnings released: EPS: HK$0.006 (vs HK$0.003 loss in FY 2021)

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Less than half of directors are independent

First half 2022 earnings released: EPS: HK$0.002 (vs HK$0 in 1H 2021)

Uni-Bio Science Group Limited to Report First Half, 2022 Results on Aug 29, 2022

Uni-Bio Science Group Limited Announces Marketing Application of Bogutai (Teriparatide Injection) Officially Accepted by the China National Medical Products Administration

Less than half of directors are independent

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2022

Uni-Bio Science Group Limited Announces Executive Changes

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021

Uni-Bio Science Group Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth

Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years

Uni-Bio Science Group Limited Announces BOSHUTAI (Acarbose Tablets) Has Been Granted Approval for Marketing in China by the National Medical Products Administration

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Uni-Bio Science Group Limited Updates on the Developmental Potential of the Group's Innovative Biologic Self-Developed Drug Recombinant Exendin-4 Injection

First half earnings released

Uni-Bio Science Group Limited to Report Q1, 2021 Results on Aug 28, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin